Ratings by Leerink (Jeffrey La Rosa)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/2/2026 | Pyxis Oncology Inc. | PYXS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2026 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/21/2025 | Senti Biosciences, Inc. | SNTI | New Coverage | Outperform (N/A) |
1.81 (0.95) |
-47.51% | Details | |
| 9/24/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/12/2025 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2024 | Janux Therapeutics | JANX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/22/2024 | Abbvie | ABBV | Upgrade | Outperform (Market Perform) |
171.73 (244.39) |
42.31% | Details | |
| 11/22/2024 | Janux Therapeutics | JANX | New Coverage | Outperform (N/A) |
46.50 (15.94) |
-65.72% | Details | |
| 1/23/2024 | Abbvie | ABBV | New Coverage | Market Perform (N/A) |
165.39 (171.73) |
3.83% | Details | |
| 1/23/2024 | Pyxis Oncology Inc. | PYXS | New Coverage | Outperform (N/A) |
2.55 (2.33) |
-8.63% | Details |
